Consequently, our data showed that the nebulization of TFF2-IFN resulted in the retention of respiratory tracts for up to 6–8 h and only marginal release into the blood afterward, suggesting that inhalation of TFF2-IFN is a proper delivery route to cure respiratory viral infections, including COVID-19 and influenza. This evidence concerns the gene IFNA1 and COVID-19.